Page 4 - Multiple Sclerosis Relapse News Today

A study found robust links between subjective fatigue and depression in early relapsing-remitting multiple sclerosis.

Changes in specific types of glycerophospholipids may contribute to reduced memory T cell subsets that are observed in people with multiple sclerosis on intermittent calorie restriction.

Although rituximab was consistently linked to better relapse outcomes vs natalizumab in new research, outcomes did not differ between dimethyl fumarate and fingolimod.

A 30-minute, automated, iPad-based NIH Toolbox Cognitive Battery may offer some key advantages over gold standard tools, with automated scoring that accounts for race/ethnicity.

Paleolithic elimination and low-saturated fat diets are associated with improvements in fatigue, cognitive dysfunction, and quality of life in patients with multiple sclerosis, new research suggests.

In a recent study of patients with early relapsing-remitting MS or clinically isolated syndrome, almost two thirds of confirmed disability accumulation occurred independently of relapses.

Time to confirmed disability worsening was longer in patients who received dimethyl fumarate, compared with those who received teriflunomide, in an analysis of real-world data.

The first European consensus on vaccination in patients with MS has been developed by the European Committee for Treatment and Research in Multiple Sclerosis and the European Academy of Neurology.

Updated European guidelines also include a recommendation for siponimod in progressive MS and more detailed information on drug use in pregnancy.

The new anti-CD20 monoclonal antibody showed significant improvement in the multiple sclerosis functional composite (MSFC) score, a measure of disability, compared with teriflunomide.